Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc
Authors:
- Katharina BormKBKatharina Borm
- Martin R. JakobsenMJMartin R. Jakobsen
- Kieran CashinKCKieran Cashin
- Jacqueline K. FlynnJFJacqueline K. Flynn
- Paula EllenbergPEPaula Ellenberg
- Lars OstergaardLOLars Ostergaard
- Benhur LeeBLBenhur Lee
- Melissa J. ChurchillMCMelissa J. Churchill
- Michael RocheMRMichael Roche
- Paul R. GorryPGPaul R. Gorry
Open Access
- 3 November 2016
- journal article
- research article
- Published by Springer Nature in Retrovirology
- Vol. 13 (1) , 1-13
Abstract
Entry of human immunodeficiency virus type 1 (HIV-1) into cells involves the interaction of the viral gp120 envelope glycoproteins (Env) with cellular CD4 and a secondary coreceptor, which is typically one of the chemokine receptors CCR5 or CXCR4. CCR5-using (R5) HIV-1 strains that display reduced sensitivity to CCR5 antagonists can use antagonist-bound CCR5 for entry. In this study, we investigated whether naturally occurring gp120 alterations in HIV-1 subtype C (C-HIV) variants exist in antiretroviral therapy (ART)-naïve subjects that may influence their sensitivity to the CCR5 antagonist maraviroc (MVC). Using a longitudinal panel of 244 R5 Envs cloned from 20 ART-naïve subjects with progressive C-HIV infection, we show that 40% of subjects (n = 8) harbored viruses that displayed incomplete inhibition by MVC, as shown by plateau’s of reduced maximal percent inhibitions (MPIs). Specifically, when pseudotyped onto luciferase reporter viruses, 16 Envs exhibited MPIs below 98% in NP2–CCR5 cells (range 79.7–97.3%), which were lower still in 293-Affinofile cells that were engineered to express high levels of CCR5 (range 15.8–72.5%). We further show that Envs exhibiting reduced MPIs to MVC utilized MVC-bound CCR5 less efficiently than MVC-free CCR5, which is consistent with the mechanism of resistance to CCR5 antagonists that can occur in patients failing therapy. Mutagenesis studies identified strain-specific mutations in the gp120 V3 loop that contributed to reduced MPIs to MVC. The results of our study suggest that some ART-naïve subjects with C-HIV infection harbor HIV-1 with reduced MPIs to MVC, and demonstrate that the gp120 V3 loop region contributes to this phenotype.Keywords
Funding Information
- Australian National Health and Medical Research Council (1086178)
- Australian Research Council
- Victorian International Postgraduate Research Scholarship
This publication has 63 references indexed in Scilit:
- A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutationsRetrovirology, 2013
- HIV-1 Escape from the CCR5 Antagonist Maraviroc Associated with an Altered and Less-Efficient Mechanism of gp120-CCR5 Engagement That Attenuates Macrophage TropismJournal of Virology, 2011
- Extreme Genetic Divergence Is Required for Coreceptor Switching in HIV-1 Subtype CJAIDS Journal of Acquired Immune Deficiency Syndromes, 2011
- Evolution of CCR5 Antagonist Resistance in an HIV-1 Subtype C Clinical IsolateJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopesVirology, 2010
- Mode of Coreceptor Use by R5 HIV Type 1 Correlates with Disease Stage: A Study of Paired Plasma and Cerebrospinal Fluid IsolatesAIDS Research and Human Retroviruses, 2009
- Heterosexual Transmission of Human Immunodeficiency Virus Type 1 Subtype C: Macrophage Tropism, Alternative Coreceptor Use, and the Molecular Anatomy of CCR5 UtilizationJournal of Virology, 2009
- Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41Proceedings of the National Academy of Sciences, 2009
- Maraviroc for Previously Treated Patients with R5 HIV-1 InfectionNew England Journal of Medicine, 2008
- Structures of the CCR5 N Terminus and of a Tyrosine-Sulfated Antibody with HIV-1 gp120 and CD4Science, 2007